ERRON KELLY: Open Payments
NPI 1508240920 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$223 in 12 payments from 9 companies in 2025. Trend: 2023 $44 · 2024 $128 · 2025 $223
Food & beverage: $223
| Company | Payments | Amount |
|---|---|---|
| Corium, LLC | 3 | $40 |
| Supernus Pharmaceuticals, Inc. | 1 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Alkermes, Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Indivior Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $13 |
Products named: Azstarys, Qelbree, ARISTADA, REXULTI, FANAPT, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE, Auvelity.
Industry payments across IN — which companies pay providers there.
